• 1. Evaluation of the relevance of DILI predictive hypotheses in early drug development: review of in vitro methodologies vs. BDDCS classification
  Rosa Chan,Leslie Z. Benet Toxicol. Res. 2018 7 358
• 2. Electrochemical synthesis of sulfamides
  Stephan P. Blum,Lukas Sch?ffer,Dieter Schollmeyer,Siegfried R. Waldvogel Chem. Commun. 2021 57 4775
• 3. A general and practical bifunctional cobalt catalytic system for N-heterocycle assembly via acceptorless dehydrogenation
  Haitao Tian,Wenxuan Xue,Jingtao Wu,Ziguang Yang,Hongcheng Lu,Conghui Tang Org. Chem. Front. 2022 9 4554
• 4. Enantioselective modification of sulfonamides and sulfonamide-containing drugs via carbene organic catalysis
  Runjiang Song,Yingguo Liu,Pankaj Kumar Majhi,Pei Rou Ng,Lin Hao,Jun Xu,Weiyi Tian,Long Zhang,Hongmei Liu,Xinglong Zhang,Yonggui Robin Chi Org. Chem. Front. 2021 8 2413

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Halopyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Halopyrimidines
• Pharmaceutical and Biochemical Products Medical Disease Classifications

Macitentan: A Comprehensive Overview

Macitentan, with the CAS registry number 441798-33-0, is a potent and selective antagonist of the endothelin receptor type A (ETA). It has garnered significant attention in the medical community due to its potential therapeutic applications in various cardiovascular and pulmonary disorders. This compound was developed to inhibit the action of endothelin-1 (ET-1), a vasoactive peptide that plays a critical role in regulating vascular tone and smooth muscle cell proliferation. Recent studies have highlighted its efficacy in treating conditions such as pulmonary hypertension (PH) and chronic thromboembolic pulmonary hypertension (CTEPH), where ET-1 signaling is hyperactive.

The development of Macitentan was driven by the need for more effective and safer therapies targeting the endothelin system. Unlike earlier ETA antagonists, which were associated with significant side effects, Macitentan demonstrates a favorable safety profile, making it a promising candidate for long-term treatment regimens. Its mechanism of action involves competitive inhibition of ET-1 binding to ETA receptors, thereby reducing vasoconstriction and inhibiting pathological smooth muscle cell growth. This dual action makes it particularly effective in managing diseases characterized by excessive ET-1 activity.

Recent clinical trials have provided compelling evidence of Macitentan's efficacy in treating pulmonary hypertension. For instance, a phase III trial demonstrated that patients treated with Macitentan experienced significant improvements in exercise capacity and quality of life compared to those receiving placebo. These findings underscore its potential as a first-line therapy for PH patients. Moreover, ongoing research is exploring its application in other conditions, such as heart failure and systemic sclerosis-associated pulmonary hypertension, where ET-1 signaling plays a pivotal role.

The pharmacokinetic profile of Macitentan is another area of interest for researchers. Studies have shown that it exhibits excellent bioavailability and a long half-life, allowing for once-daily dosing. This convenience enhances patient adherence to treatment regimens, which is crucial for chronic diseases like PH. Additionally, its metabolism via cytochrome P450 enzymes has been well-characterized, providing insights into potential drug-drug interactions and guiding clinical dosing strategies.

In terms of safety, Macitentan has been generally well-tolerated in clinical trials. Common adverse effects include headache, dizziness, and nasopharyngitis, which are typically mild to moderate in severity. However, careful monitoring is required for patients with pre-existing liver or kidney dysfunction, as these conditions may affect drug clearance and increase the risk of adverse events.

The discovery and development of Macitentan represent a significant advancement in endothelin receptor antagonist therapy. By leveraging cutting-edge research on ET receptor signaling pathways, scientists have created a compound that not only addresses unmet medical needs but also sets a new standard for safety and efficacy in this therapeutic class.

• 441798-39-6(Macitentan Impurity 51)
• 1258428-05-5(Macitentan-d)
• 441796-13-0(N-Despropyl-N-ethyl Macitentan)
• 2211059-00-4(N-5-(4-Bromophenyl)-6-2-(2-pyrimidinyloxy)ethoxy-4-pyrimidinyl-N'-propyl-sulfamide)
• 441796-09-4(N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-(phenylmethyl)sulfamide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)